hVIVO to Lead Groundbreaking Phase 3 Trial for Whooping Cough Vaccine

The latest update is out from Open Orphan Plc ( (GB:HVO) ).

hVIVO plc has signed a letter of intent with ILiAD Biotechnologies to conduct the world’s first pivotal Phase 3 human challenge trial for BPZE1, a next-generation whooping cough vaccine candidate. This collaboration marks a significant step in tackling the global resurgence of whooping cough, as current vaccines are insufficient, with cases rising dramatically in recent years. The trial is expected to start in the second half of 2025 and aims to expedite the vaccine’s development, offering comprehensive protection against Bordetella pertussis infections. This strategic move could position hVIVO at the forefront of innovative vaccine testing, benefiting stakeholders by potentially bringing a critical vaccine to market more swiftly.

More about Open Orphan Plc

hVIVO plc is a fast-growing specialist contract research organisation (CRO) and a global leader in testing infectious and respiratory disease vaccines and therapeutics through human challenge clinical trials. The company offers comprehensive early clinical development services to a diverse client base, including several of the world’s largest biopharma companies. With a unique portfolio of human challenge models, hVIVO provides a wide range of services, including drug development, clinical consultancy, and laboratory offerings. The company operates the world’s largest commercial human challenge trial unit in London.

YTD Price Performance: -4.39%

Average Trading Volume: 2,962,324

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £133.4M

See more insights into HVO stock on TipRanks’ Stock Analysis page.